Inhibition of the DPP-4 system trends a new approach in the management of Type-2 diabetes by virtue of its effects on extending the half-life of glucose-dependent insulinotropic peptide (GLP-1) and glucagon-like peptide-1 (GIP) [8]. Here, DPP4 is linked to type 2 diabetes mellitus.